Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of atypicalemerging pneumonia. The clinical spectrum varies from an asymptomatic or mild illness toa serious illness with a high risk of mortality. The most severely affected patients (5%)present an acute respiratory distress syndrome (ARDS), requiring assistance withmechanical ventilation in intensive care.In 2003, persistent lung damage was observed in a third of patients in a Singaporeancohort one year after SARS-CoV infection. A Chinese study showed that 27.3% of theirSARS-CoV patients presented a decreased carbon monoxide diffusion (DLCO) and 21.5% ofpulmonary fibrosis lesions.Due to the very recent emergence of SARS-CoV-2, no data is currently available oflong-term outcome of these patients. However, recent publications including short-term CTmonitoring suggest the genesis of fibrotic pulmonary parenchymal sequelae.In view of these data, the investigators can fear the occurrence of pulmonary sequelae inpatients infected with SARS-CoV-2. It is therefore essential to evaluate the evolution ofthe respiratory status of the most severe patients who have had a stay in intensive carewith respiratory assistance.

The purpose of the study is to evaluate the presence of early vascular aging 6 months and12 months after COVID-19 infection.

Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to areference method.

Multicenter observational study of diagnostic test validation (Research Involving theHuman Person, type 3) In addition to the diagnosis by the reference method(nasopharyngeal swab), the patient will be asked to provide a saliva sample via asalivary spit. The clinical circumstances of the diagnosis, the age of the patient, theassociated terrain (diabetes, immunodepression, pregnancy) will be noted. Thenasopharyngeal and saliva samples will be analyzed in Cayenne and the remaining sampleswill be frozen and stored at the CRB before being sent to the University Hospital of Caenfor analysis and concordance verification.The expected benefits are:Possibility of repeating tests in the same person more easily due to the absence of painand thus reduce the barriers to diagnosis and screening.Possibility of self-sampling, which could simply be sent to the laboratory, which wouldrelieve the diagnostic sites that mobilize staff and require a fairly heavy organization.Avoid long waiting lines that can be an obstacle and lead to a renunciation of thediagnosis.

To measure the frequency of persistent liver dysfunction (raised liver enzymes, serumalbumin, prothrombin time, etc) in recovered COVID -19 patients.To compare the hepatic manifestations in post COVID -19 patients with and without liverdisease

Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinesmay reduce the transmission of and achieve population immunity against the COVID-19pandemic, which accounted for more than 3.75million deaths worldwide. With World HealthOrganization's (WHO) effort on ensuring equitable access to COVID-19 vaccines,vaccination rate may increase in the near future.On the other hand, vaccination hesitancy has emerged as a major hindrance on the globalvaccination campaigns in certain areas due to safety concerns, social factors, and publichealth policies. For instance, a recent survey conducted in Hong Kong showed a lowvaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination eventsrelayed by the social media maybe reasons for vaccination hesitancy. Among which,cerebrovascular accidents (CVA) after vaccination were one of the most frequentlyreported post-vaccination events. These reports ranged from ischemic strokes in elderlypatients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise"young-and-fit" adults. While many of these events were investigated by the COVID-19immunization expert committee, an important premise to address the apprehension of CVAafter vaccination is the provision of evidence-based information of the impact ofCOVID-19 vaccines on brain health.In this prospective, longitudinal, observational study, we aim to elucidate therelationship between COVID-19 vaccines and cerebrovascular health in healthy citizens ina population-based cohort.

Decentralized clinical study designed to collect further cough sounds, self-reportedsymptoms, and medical treatment questionnaires from participants enrolled on theCOVID-Cough Study ("Study 1").The aim of this further data collection study ("Study 2") is to: 1. develop an understanding of changes in cough sounds associated with COVID-19 and how they alter during the disease; 2. develop an understanding of other causes of COVID-19-like symptoms and their associated cough sound patterns; and 3. gain a broader understanding of the clinical outcomes of individuals who present for COVID-19 testing.

The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2(SARS CoV-2), an emerging coronavirus, which has already infected 192 million people witha case fatality rate close to 2%. About 5% of patients infected with SARS CoV-2 have acritical form with organ failure. Among critical patients admitted to intensive care,about 70% of them will require ventilatory assistance by invasive mechanical ventilation(MV) with a mortality rate of 35% and a median MV duration of 12 days. The most severelung damage resulting from SARS CoV-2 infection is the acute respiratory distresssyndrome (ARDS). The virus infects alveolar epithelial cells and capillary endothelialcells leading to an activation of endothelium, hypercoagulability and thrombosis ofpulmonary capillaries. This results in abnormal ventilation / perfusion ratios andprofound hypoxemia. To date, the therapeutic management of severe SARS CoV-2 pneumonialay on the early use of corticosteroids and Interleukin-6 (IL-6) receptor antagonist,which both reduce the need of MV and mortality. The risk factors of death in IntensiveCare Unit (ICU) are: advanced age, severe obesity, coronary heart disease, active cancer,severe hypoxemia, and hepatic and renal failure on admission. Among MV patients, thedeath rate is doubled in those with both reduced thoracopulmonary compliance and elevatedD-dimer levels. Patients with severe alveolar damage are at risk of progressing towardsirreversible pulmonary fibrosis, the incidence of which still remain unknown. Thediagnosis of pulmonary fibrosis is based on histology but there are some non-invasivealternative methods (serum or bronchoalveolar biomarkers, chest CT scan). We aim toassess the incidence of pulmonary fibrosis in patients with severe SARS CoV-2 relatedpneumonia. We will investigate the prognostic impact of fibrosis on mortality and thenumber of days alive free from MV at Day 90. Finally, we aim to identify risk factors offibrosis.

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for thecoronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, onDecember 31, 2019. It has rapidly spread globally with approximately 157,343,044confirmed cases and 3,278,510 deaths till 7th May, 2021 [1]. World Health Organization(WHO) declared COVID- 19 pandemic on 11th March 2020.The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic whichis the most troublesome challenge to public health. The second wave is running and nobodyknows where we are in the course of this disease. It becomes a significant challenge forthe public health, science, and medical sectors [2].According to the World Health Organization, about 80% of infections are mild orasymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5%are critical infections, which require ventilation.We are learning something new every day. Our understanding of the pandemic is growing andchanging daily. The world is focusing on the short term - flattening the curve, treatingthe sick and discovering a vaccine. But there is more to this pandemic than the shortterm.We know a lot about the transmission and clinical feature of COVID-19, but relativelylittle about what happens after someone recovers. Much is still unknown about howCOVID-19 will affect people over time. There's still much to be learned from those whohave recovered from COVID-19.

Gazelle COVID-19 is a fluorescent lateral flow immunoassay and accompanying Readerintended for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasalswab specimens from individuals who are suspected of COVID-19 by their healthcareprovider within 5 days of symptom onset. The study will be conducted To obtain data tomeasure the positive percent agreement and negative percent agreement of the GazelleCOVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).Thestudy will assess Gazelle COVID-19 Test performance using dual mid-turbinate nasal swabsamples. This study will primarily assess Gazelle COVID-19 Test performance onsymptomatic subjects (within five days of onset of symptoms) at point of care (POC). Asubset of asymptomatic subjects will be enrolled after the symptomatic subject enrollmentis complete.